TEVA Teva- Pharmaceutical Industries Dashboard

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Company profile

Ticker

TEVA, TEVJF

Exchange

NYSE

Website

www.tevapharm.com

CEO

Kaare Schultz

Incorporated

Israel

Location

Israel

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Warner Chilcott • Abbvie ...

Former names

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

SEC CIK

0000818686

Corporate docs

Articles of Incorporation & Bylaws

TEVA stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

10 Health Care Stocks Showing Unusual Options Activity In Today's Session

2 Aug 21

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. Unusual trading activity could push option prices to exaggerated or underestimated levels.

Analyzing Teva Pharmaceutical Indus's Unusual Options Activity

29 Jul 21

On Thursday, shares of Teva Pharmaceutical Indus (NYSE:TEVA) saw unusual options activity. After the option alert, the stock price moved down to $9.72.

Raymond James Maintains Outperform on Teva Pharmaceutical Indus, Lowers Price Target to $14

29 Jul 21

Raymond James analyst Elliot Wilbur maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform and lowers the price target from $15 to $14.

Wells Fargo Maintains Equal-Weight on Teva Pharmaceutical Indus, Lowers Price Target to $11

29 Jul 21

62 Biggest Movers From Yesterday

29 Jul 21

Press releases

Pro users get this 30m faster

Thinking about buying stock in Teva Pharmaceutical, Tencent Music Entertainment, Xpeng, Vipshop Holdings, or Asensus Surgical?

28 Jul 21

NEW YORK, July 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TEVA, TME, XPEV, VIPS, and ASXC.

NRx Pharmaceuticals Announces Partnership with the Israel Institute for Biological Research to Complete Development and Commercialization of BriLife™ COVID Vaccine

12 Jul 21

TEL AVIV, Israel and RADNOR, Pa., July 12, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NASDAQ:

Helius Medical Technologies, Inc. Appoints Antonella Favit-Van Pelt, M.D., Ph.D. as Chief Medical Officer

8 Jul 21

NEWTOWN, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the

Teva to Host Conference Call to Discuss Second Quarter 2021 Financial Results at 8 a.m. ET on July 28, 2021

1 Jul 21

Teva and Bioeq Announce Commercial Partnership for Biosimilar

28 Jun 21

Calendar

28 Jul 21

4 Aug 21

31 Dec 21

Financial summary

Financial statements Chart TEVA financial data

Quarter (USD)	Jun 21	Mar 21	Dec 20	Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	2.44B	2.44B	2.44B	2.44B	2.44B	2.44B
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	(positive/no burn)	243.33M	(positive/no burn)	(positive/no burn)
Cash used (since last report)	n/a	n/a	n/a	284.85M	n/a	n/a
Cash remaining	n/a	n/a	n/a	2.15B	n/a	n/a
Runway (months of cash)	n/a	n/a	n/a	8.8	n/a	n/a

Beta Read what these cash burn values mean

Recent insider trades

TEVA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	#Shares	#Remaining
14 Jun 21	Barer Sol J	Restricted Share Units Ordinary Shares	Grant	Aquire A	No	No	25,791	25,791
14 Jun 21	Crane Rosemary A	Restricted Share Units Ordinary Shares	Grant	Aquire A	No	No	14,479	14,479
14 Jun 21	Elstein Amir	Restricted Share Units Ordinary Shares	Grant	Aquire A	No	No	14,479	14,479
14 Jun 21	Halfon Jean Michel	Restricted Share Units Ordinary Shares	Grant	Aquire A	No	No	14,479	14,479
14 Jun 21	Abbas Hussain	Restricted Share Units Ordinary Shares	Grant	Aquire A	No	No	14,479	14,479

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

TEVA institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	2	EXIT
Opened positions	0	2	EXIT
Closed positions	2	0	NEW
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	1.26B	EXIT
Total shares	0	130.45M	EXIT
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change
Capital Research Global Investors	0	-130.14M	EXIT
Wellington Management	0	-310.79K	EXIT

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Akorn • Teligent • Spectrum Pharmaceuticals • Actavis • Nektar Therapeutics • Neurocrine Biosciences • Acorda Therapeutics • Innoviva • NeuBase Therapeutics • Amphastar Pharmaceuticals

Management Discussion

The discussion that follows includes a comparison of our results of operations and liquidity and capital resources for fiscal years 2020 and 2019. For a comparison of our results of operations and financial condition for fiscal years 2019 and 2018, see “Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our 2019 Annual Report on Form10-K,

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: AMCo, Ameri, arguing, arisi, aser, assigned, Aurobindo, buying, ca, comp, Delhi, dis, drawn, driven, enrichment, eventual, FASB, fraud, fraudulent, fremanezumab, Green, Index, interference, Irvine, Lanham, libel, missed, monopolization, Mylan, NaNaccount, National, ng, opportunity, pace, paused, plausibly, proactively, promulgated, PTAB, Racketeer, reassessment, refractory, rehensive, satisfactorily, scheme, thr, Travere, Tribunal, unfair, unjust, Washington, Waymade

Removed: acetate, bortezomib, combining, competing, Draft, glatiramer, memantine, Supplementary

From filing 10-Q 2021 Q2